LONG-TERM FOLLOW-UP OF 46 PATIENTS WITH ANTI-(U1)snRNP ANTIBODIES
The records of 46 patients with anti-(Ul)snRNP antibodies and a minimal period of follow-up after first clinical presentation of at least 5 yr were examined with emphasis on symptoms contributing to established criteria of SLE, systemic sclerosis (SSc), RA or dermato- or polymyositis (DM/PM). At fir...
Gespeichert in:
| Veröffentlicht in: | Rheumatology (Oxford, England) England), 1994-12, Vol.33 (12), p.1117-1120 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1120 |
|---|---|
| container_issue | 12 |
| container_start_page | 1117 |
| container_title | Rheumatology (Oxford, England) |
| container_volume | 33 |
| creator | VAN DEN HOOGEN, F. H. J. SPRONK, P. E. BOERBOOMS, A. M. T. BOOTSMA, H. DE ROOIJ, D. J. R. A. M. KALLENBERG, C. G. M. VAN DE PUTTE, L. B. A. |
| description | The records of 46 patients with anti-(Ul)snRNP antibodies and a minimal period of follow-up after first clinical presentation of at least 5 yr were examined with emphasis on symptoms contributing to established criteria of SLE, systemic sclerosis (SSc), RA or dermato- or polymyositis (DM/PM). At first clinical presentation 13 (28%) of the 46 patients studied fulfilled ARA-criteria for SLE (n = 10), RA (n = 2) and SSc (n = 1), and 33 (72%) were classified as mixed connective tissue disease (MCTD). During follow-up 18 patients initially classified as MCTD were now classified as SLE (n = 5), SSc (n = 7), RA (n =3), or a combination of these disorders (n = 3). A transformation of MCTD towards these connective tissue diseases occurred 2.6 ± 3 yr (mean ± S.D.) after first clinical presentation. At the end of the follow-up period 67% of the patients fulfilled ARA criteria for SLE, SSc, RA or a combination of these diseases. The majority of patients with anti-(Ul)snRNP antibodies have or will develop a classified connective tissue disease within 5 yr after clinical presentation. This undermines the concept of MCTD being a distinct clinical entity. |
| doi_str_mv | 10.1093/rheumatology/33.12.1117 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_195655338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>23436489</sourcerecordid><originalsourceid>FETCH-LOGICAL-c235t-f94916a0a57e5667249752adbaa27751b90b42905354bb52d840c7e359def7cd3</originalsourceid><addsrcrecordid>eNpNkE1PwkAQhjdGExH9DTae9FDY3enusseChZbUtoESjJfN9ktBoNiWRP69IIZ4mneS95lJHoTuCe4QLKFbfeS7tW7KVfm-7wJ0CO0QQsQFahGLUxMD0MtzptY1uqnrJcaYEei1kO2HwciMncmLMQx9P5ybs8gIh4bFjciOPSeIp8bci13DDmLPfJyRp3ozCaLftR8-e870Fl0VelXnd3-zjWZDJx64ph-OvIHtmykF1piFtCThGmsmcsa5oJYUjOos0ZoKwUgicWJRiRkwK0kYzXoWTkUOTGZ5IdIM2ujhdHdblV-7vG7UstxVm8NLRSTjjAH0DiVxKqVVWddVXqhttVjraq8IVkdd6r8uBaAIVUddB9I8kYu6yb_PmK4-FRcgmHJf35TbFzEPxpEaww8hZGn9</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>195655338</pqid></control><display><type>article</type><title>LONG-TERM FOLLOW-UP OF 46 PATIENTS WITH ANTI-(U1)snRNP ANTIBODIES</title><source>Alma/SFX Local Collection</source><creator>VAN DEN HOOGEN, F. H. J. ; SPRONK, P. E. ; BOERBOOMS, A. M. T. ; BOOTSMA, H. ; DE ROOIJ, D. J. R. A. M. ; KALLENBERG, C. G. M. ; VAN DE PUTTE, L. B. A.</creator><creatorcontrib>VAN DEN HOOGEN, F. H. J. ; SPRONK, P. E. ; BOERBOOMS, A. M. T. ; BOOTSMA, H. ; DE ROOIJ, D. J. R. A. M. ; KALLENBERG, C. G. M. ; VAN DE PUTTE, L. B. A.</creatorcontrib><description>The records of 46 patients with anti-(Ul)snRNP antibodies and a minimal period of follow-up after first clinical presentation of at least 5 yr were examined with emphasis on symptoms contributing to established criteria of SLE, systemic sclerosis (SSc), RA or dermato- or polymyositis (DM/PM). At first clinical presentation 13 (28%) of the 46 patients studied fulfilled ARA-criteria for SLE (n = 10), RA (n = 2) and SSc (n = 1), and 33 (72%) were classified as mixed connective tissue disease (MCTD). During follow-up 18 patients initially classified as MCTD were now classified as SLE (n = 5), SSc (n = 7), RA (n =3), or a combination of these disorders (n = 3). A transformation of MCTD towards these connective tissue diseases occurred 2.6 ± 3 yr (mean ± S.D.) after first clinical presentation. At the end of the follow-up period 67% of the patients fulfilled ARA criteria for SLE, SSc, RA or a combination of these diseases. The majority of patients with anti-(Ul)snRNP antibodies have or will develop a classified connective tissue disease within 5 yr after clinical presentation. This undermines the concept of MCTD being a distinct clinical entity.</description><identifier>ISSN: 1462-0324</identifier><identifier>EISSN: 1462-0332</identifier><identifier>DOI: 10.1093/rheumatology/33.12.1117</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Anti-(Ul)snRNP antibodies ; Follow-up ; Mixed connective tissue disease ; Rheumatoid arthritis ; Systemic lupus erythematosus ; Systemic sclerosis ; Undifferentiated connective tissue disease</subject><ispartof>Rheumatology (Oxford, England), 1994-12, Vol.33 (12), p.1117-1120</ispartof><rights>Copyright Oxford University Press(England) Dec 1994</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c235t-f94916a0a57e5667249752adbaa27751b90b42905354bb52d840c7e359def7cd3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>VAN DEN HOOGEN, F. H. J.</creatorcontrib><creatorcontrib>SPRONK, P. E.</creatorcontrib><creatorcontrib>BOERBOOMS, A. M. T.</creatorcontrib><creatorcontrib>BOOTSMA, H.</creatorcontrib><creatorcontrib>DE ROOIJ, D. J. R. A. M.</creatorcontrib><creatorcontrib>KALLENBERG, C. G. M.</creatorcontrib><creatorcontrib>VAN DE PUTTE, L. B. A.</creatorcontrib><title>LONG-TERM FOLLOW-UP OF 46 PATIENTS WITH ANTI-(U1)snRNP ANTIBODIES</title><title>Rheumatology (Oxford, England)</title><description>The records of 46 patients with anti-(Ul)snRNP antibodies and a minimal period of follow-up after first clinical presentation of at least 5 yr were examined with emphasis on symptoms contributing to established criteria of SLE, systemic sclerosis (SSc), RA or dermato- or polymyositis (DM/PM). At first clinical presentation 13 (28%) of the 46 patients studied fulfilled ARA-criteria for SLE (n = 10), RA (n = 2) and SSc (n = 1), and 33 (72%) were classified as mixed connective tissue disease (MCTD). During follow-up 18 patients initially classified as MCTD were now classified as SLE (n = 5), SSc (n = 7), RA (n =3), or a combination of these disorders (n = 3). A transformation of MCTD towards these connective tissue diseases occurred 2.6 ± 3 yr (mean ± S.D.) after first clinical presentation. At the end of the follow-up period 67% of the patients fulfilled ARA criteria for SLE, SSc, RA or a combination of these diseases. The majority of patients with anti-(Ul)snRNP antibodies have or will develop a classified connective tissue disease within 5 yr after clinical presentation. This undermines the concept of MCTD being a distinct clinical entity.</description><subject>Anti-(Ul)snRNP antibodies</subject><subject>Follow-up</subject><subject>Mixed connective tissue disease</subject><subject>Rheumatoid arthritis</subject><subject>Systemic lupus erythematosus</subject><subject>Systemic sclerosis</subject><subject>Undifferentiated connective tissue disease</subject><issn>1462-0324</issn><issn>1462-0332</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><recordid>eNpNkE1PwkAQhjdGExH9DTae9FDY3enusseChZbUtoESjJfN9ktBoNiWRP69IIZ4mneS95lJHoTuCe4QLKFbfeS7tW7KVfm-7wJ0CO0QQsQFahGLUxMD0MtzptY1uqnrJcaYEei1kO2HwciMncmLMQx9P5ybs8gIh4bFjciOPSeIp8bci13DDmLPfJyRp3ozCaLftR8-e870Fl0VelXnd3-zjWZDJx64ph-OvIHtmykF1piFtCThGmsmcsa5oJYUjOos0ZoKwUgicWJRiRkwK0kYzXoWTkUOTGZ5IdIM2ujhdHdblV-7vG7UstxVm8NLRSTjjAH0DiVxKqVVWddVXqhttVjraq8IVkdd6r8uBaAIVUddB9I8kYu6yb_PmK4-FRcgmHJf35TbFzEPxpEaww8hZGn9</recordid><startdate>199412</startdate><enddate>199412</enddate><creator>VAN DEN HOOGEN, F. H. J.</creator><creator>SPRONK, P. E.</creator><creator>BOERBOOMS, A. M. T.</creator><creator>BOOTSMA, H.</creator><creator>DE ROOIJ, D. J. R. A. M.</creator><creator>KALLENBERG, C. G. M.</creator><creator>VAN DE PUTTE, L. B. A.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>199412</creationdate><title>LONG-TERM FOLLOW-UP OF 46 PATIENTS WITH ANTI-(U1)snRNP ANTIBODIES</title><author>VAN DEN HOOGEN, F. H. J. ; SPRONK, P. E. ; BOERBOOMS, A. M. T. ; BOOTSMA, H. ; DE ROOIJ, D. J. R. A. M. ; KALLENBERG, C. G. M. ; VAN DE PUTTE, L. B. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c235t-f94916a0a57e5667249752adbaa27751b90b42905354bb52d840c7e359def7cd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Anti-(Ul)snRNP antibodies</topic><topic>Follow-up</topic><topic>Mixed connective tissue disease</topic><topic>Rheumatoid arthritis</topic><topic>Systemic lupus erythematosus</topic><topic>Systemic sclerosis</topic><topic>Undifferentiated connective tissue disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VAN DEN HOOGEN, F. H. J.</creatorcontrib><creatorcontrib>SPRONK, P. E.</creatorcontrib><creatorcontrib>BOERBOOMS, A. M. T.</creatorcontrib><creatorcontrib>BOOTSMA, H.</creatorcontrib><creatorcontrib>DE ROOIJ, D. J. R. A. M.</creatorcontrib><creatorcontrib>KALLENBERG, C. G. M.</creatorcontrib><creatorcontrib>VAN DE PUTTE, L. B. A.</creatorcontrib><collection>Istex</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Rheumatology (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VAN DEN HOOGEN, F. H. J.</au><au>SPRONK, P. E.</au><au>BOERBOOMS, A. M. T.</au><au>BOOTSMA, H.</au><au>DE ROOIJ, D. J. R. A. M.</au><au>KALLENBERG, C. G. M.</au><au>VAN DE PUTTE, L. B. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LONG-TERM FOLLOW-UP OF 46 PATIENTS WITH ANTI-(U1)snRNP ANTIBODIES</atitle><jtitle>Rheumatology (Oxford, England)</jtitle><date>1994-12</date><risdate>1994</risdate><volume>33</volume><issue>12</issue><spage>1117</spage><epage>1120</epage><pages>1117-1120</pages><issn>1462-0324</issn><eissn>1462-0332</eissn><abstract>The records of 46 patients with anti-(Ul)snRNP antibodies and a minimal period of follow-up after first clinical presentation of at least 5 yr were examined with emphasis on symptoms contributing to established criteria of SLE, systemic sclerosis (SSc), RA or dermato- or polymyositis (DM/PM). At first clinical presentation 13 (28%) of the 46 patients studied fulfilled ARA-criteria for SLE (n = 10), RA (n = 2) and SSc (n = 1), and 33 (72%) were classified as mixed connective tissue disease (MCTD). During follow-up 18 patients initially classified as MCTD were now classified as SLE (n = 5), SSc (n = 7), RA (n =3), or a combination of these disorders (n = 3). A transformation of MCTD towards these connective tissue diseases occurred 2.6 ± 3 yr (mean ± S.D.) after first clinical presentation. At the end of the follow-up period 67% of the patients fulfilled ARA criteria for SLE, SSc, RA or a combination of these diseases. The majority of patients with anti-(Ul)snRNP antibodies have or will develop a classified connective tissue disease within 5 yr after clinical presentation. This undermines the concept of MCTD being a distinct clinical entity.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><doi>10.1093/rheumatology/33.12.1117</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-0324 |
| ispartof | Rheumatology (Oxford, England), 1994-12, Vol.33 (12), p.1117-1120 |
| issn | 1462-0324 1462-0332 |
| language | eng |
| recordid | cdi_proquest_journals_195655338 |
| source | Alma/SFX Local Collection |
| subjects | Anti-(Ul)snRNP antibodies Follow-up Mixed connective tissue disease Rheumatoid arthritis Systemic lupus erythematosus Systemic sclerosis Undifferentiated connective tissue disease |
| title | LONG-TERM FOLLOW-UP OF 46 PATIENTS WITH ANTI-(U1)snRNP ANTIBODIES |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T01%3A29%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LONG-TERM%20FOLLOW-UP%20OF%2046%20PATIENTS%20WITH%20ANTI-(U1)snRNP%20ANTIBODIES&rft.jtitle=Rheumatology%20(Oxford,%20England)&rft.au=VAN%20DEN%20HOOGEN,%20F.%20H.%20J.&rft.date=1994-12&rft.volume=33&rft.issue=12&rft.spage=1117&rft.epage=1120&rft.pages=1117-1120&rft.issn=1462-0324&rft.eissn=1462-0332&rft_id=info:doi/10.1093/rheumatology/33.12.1117&rft_dat=%3Cproquest_cross%3E23436489%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=195655338&rft_id=info:pmid/&rfr_iscdi=true |